All In Biotech

Drug Trial Radar · NCT04980482

Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

43

Actual

Start

Oct 29, 2021

Primary completion

Mar 13, 2025

Study completion May 21, 2025

Sponsor

Lead sponsor
Arbutus Biopharma CorporationIndustry
Sponsor type
Industry
First posted
Jul 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in subjects with CHB.

Conditions

  • Chronic Hepatitis b

Interventions

  • AB-729Drug

    subcutaneous injection

  • Peg-IFNα-2aDrug

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Frequency and Severity of Treatment Emergent Adverse Events (TEAEs), Discontinuations Due to AEs and Lab Abnormalities After Dosing With AB-729 Plus Peg-IFNα-2aTime frame: Up to 124 weeks

Locations

17 sites in 7 countries. Site status is shown where the registry gives one.

  • Arizona Liver Health

    Chandler, Arizona

  • Arizona Liver Health

    Tucson, Arizona

  • Research and Education, Inc.

    San Diego, California

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Henry Ford Health System

    Detroit, Michigan

  • ID Care

    Hillsborough, New Jersey

  • Nepean Hospital

    Kingswood, New South Wales, Australia

  • St Vincent's Hospital Melbourne

    Melbourne, Victoria, Australia

  • Prince of Wales Hospital, The Chinese University of Hong Kong

    Hong Kong, Hong Kong

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Arensia Exploratory Medicine Moldova

    Chisinau, Moldova

  • Asan Medical Center

    Seoul, South Korea

  • Pusan National University Hospital

    Pusan, Republic of Korea, South Korea

  • Chia-Yi Christian Hospital

    Chiayi City, Taiwan

  • Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Taiwan

  • Medical Center of Limited Liability Company Harmoniya Krasy

    Kyiv, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.